Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 Next >
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause
From Bayer
Via Business Wire
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
From Bayer
Via Business Wire
Bayer Statement on Win in Jones Roundup™ Trial
From Bayer
Via Business Wire
Bayer and Salus Optima Partner on AI-Enabled Healthy Aging Journey
From Bayer
Via Business Wire
Bayer Earns Top Score in Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index for Sixth Consecutive Year
From Bayer
Via Business Wire
Bayer and CrossBay Medical to develop novel Intrauterine System Inserter
From Bayer
Via Business Wire
Bayer and Hurdle launch precision health strategic partnership
From Bayer
Via Business Wire
Bayer Announces Publication of Health Economic Model Evaluation at RSNA, Providing New Insights Into Cost Effectiveness and Capacity Needs of Supplemental Screening Modalities for Dense Breasts
From Bayer
Via Business Wire
Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
From Bayer
Via Business Wire
Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination
From Bayer
Via Business Wire
Bayer Provides Update on Aliqopa® (copanlisib)
From Bayer
Via Business Wire
New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment
From Bayer
Via Business Wire
Bayer and Recursion focus research collaboration on Oncology
From Bayer
Via Business Wire
Alka-Seltzer® Teams Up with George Kittle to Encourage Football Fans to ‘Say Yes’ to Going Big on Game Days
From Bayer
Via Business Wire
New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia® (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies
From Bayer
Via Business Wire
FieldView and Combyne Platform Integration Helps Farmers Better Manage Grain Marketing and Build Profitability Insights
From Bayer
Via Business Wire
Bayer Unveils Latest Data from Oncology Portfolio at ESMO Congress 2023
From Bayer
Via Business Wire
Bayer and Dollar General Partner to Increase Access to Fruit and Veggies, Celebrate National School Lunch Week
From Bayer
Via Business Wire
Bayer to Partner With Twist Bioscience to Accelerate Drug Discovery
From Bayer
Via Business Wire
The Menopause Society Annual Meeting 2023: Bayer to present latest real-world evidence of menopausal symptoms and their treatment
From Bayer
Via Business Wire
Bayer’s Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology
From Bayer
Via Business Wire
Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure
From Bayer
Via Business Wire
Bayer and Kroger Team to Help Improve Access to Health and Nutrition in Rural America
From Bayer
Via Business Wire
FieldView Rolls Out New Capabilities For Post-Harvest Analysis and Reporting
From Bayer
Via Business Wire
One in Four American Adults Would Rather Not Know They Have Cancer
From Bayer
Via Business Wire
Bayer Donates $500K to Support Maui Community After Devastating Fires
From Bayer
Via Business Wire
The Terror is Hatching: Bayer Unveils Upcoming “Rootworm Week”
From Bayer
Via Business Wire
Bayer Earns Top Score on 2023 Disability Equality Index
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.